乳糜泻 中国就医指南

Celiac disease is a chronic, immune-mediated systemic disorder triggered by dietary gluten and related prolamins in genetically susceptible individuals. It primarily affects the small intestine, causing villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis—hallmarks of gluten-induced enteropathy. Pathogenesis involves a complex interplay of genetic, environmental, and immunologic factors: over 95% of patients carry HLA-DQ2 or HLA-DQ8 haplotypes, which present deamidated gliadin peptides to CD4+ T cells, initiating an adaptive immune response. Concurrently, tissue transglutaminase (tTG) autoantibodies are produced, contributing to mucosal damage and extraintestinal manifestations. Non-HLA genes (e.g., IL2, SH2B3) further modulate risk. Epidemiologically, celiac disease affects approximately 1% of the global population, though prevalence varies regionally—ranging from 0.3% to 2.6%—and remains significantly underdiagnosed in China, where seroprevalence studies suggest ~0.4–0.7% in general populations and higher rates (up to 2.3%) in high-risk groups such as first-degree relatives or patients with type 1 diabetes or autoimmune thyroiditis. Key risk factors include family history (10–20% risk among first-degree relatives), HLA genotype, early infant feeding practices (e.g., timing of gluten introduction), gastrointestinal infections (e.g., recurrent rotavirus), and comorbid autoimmune conditions. Untreated celiac disease leads to malabsorption of micronutrients (iron, folate, vitamin D, B12), osteoporosis, infertility, neurological complications (e.g., gluten ataxia, peripheral neuropathy), and a 2–4-fold increased risk of non-Hodgkin lymphoma and small bowel adenocarcinoma. Quality of life is profoundly impacted: patients report persistent fatigue, abdominal pain, bloating, diarrhea or constipation, anxiety, depression, social isolation due to dietary restrictions, and reduced work productivity. Even asymptomatic or 'silent' cases show histologic damage and elevated long-term morbidity risks. Diagnosis requires serologic testing (IgA anti-tissue transglutaminase, IgA endomysial antibodies) followed by confirmatory duodenal biopsy while on a gluten-containing diet. Genetic testing for HLA-DQ2/DQ8 is useful for ruling out disease when serology is equivocal. Lifelong strict adherence to a gluten-free diet (GFD) remains the only evidence-based treatment—eliminating wheat, barley, rye, and contaminated oats. Nutritional counseling, regular monitoring of serologic response and bone mineral density, and screening for associated autoimmune disorders are essential components of comprehensive care. Patient education, access to certified gluten-free foods, and psychosocial support significantly improve long-term outcomes and quality of life.

# 乳糜泻治疗方案与费用明细（消化内科）

一、非手术/保守治疗（一线首选）

• •适用人群：确诊乳糜泻患者（血清tTG-IgA阳性+小肠活检示绒毛萎缩）
• •核心方案：严格无麸质饮食（GFD）管理 + 营养支持 + 定期随访
• •费用明细（年均）：

- 血清tTG-IgA复查（每6–12月）：¥120–¥280/次 - 小肠镜复查（首年及症状复发时）：¥2,800–¥4,500（含病理） - 营养科门诊随访（4次/年）：¥400–¥800

二、药物治疗（二线，仅限难治性病例）

• •适用人群：严格GFD 12个月后仍持续腹泻、体重下降或黏膜未愈者
• •方案：布地奈德口服缓释剂（≤9mg/d，疗程8–12周）
• •费用：¥1,200–¥3,500/疗程（国产仿制药至原研药）

三、手术/介入方案

• •乳糜泻本身无需手术；仅当并发肠淋巴管扩张症、难治性溃疡或肠梗阻等并发症时，按消化外科指征处理。此类属并发症处置，非乳糜泻根治手段。

四、特殊复杂情况

• •难治性乳糜泻（RCD）Ⅰ型：强化营养支持+免疫抑制（硫唑嘌呤），年费用¥15,000–¥35,000；
• •RCDⅡ型（克隆性T细胞增殖）：需转血液科评估，可能行自体造血干细胞移植，总费用≥¥300,000（医保部分报销）。

五、方案快速选择指南

• •初诊轻症：首选严格GFD+基础随访（年预算¥5,000内）；
• •经济受限者：聚焦医保覆盖的tTG检测+基层营养指导（年¥2,000起）；
• •反复不愈者：启动药物干预+小肠镜复评（首年预算¥10,000–¥20,000）。